MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
OPKO Health Book Value 2011-2026 | OPK
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value OPKO Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.37 B | 1.39 B | 1.56 B | 1.69 B | 1.67 B | 1.61 B | 1.79 B | 1.89 B | 2.09 B | 1.98 B | 836 M | 873 M | 203 M | 161 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.09 B | 161 M | 1.36 B |
Quarterly Book Value OPKO Health
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.3 B | 1.31 B | 1.4 B | 1.4 B | 1.25 B | 1.44 B | 1.54 B | 1.55 B | 1.56 B | 1.63 B | - | 1.61 B | 1.69 B | 1.77 B | 1.74 B | 1.7 B | 1.67 B | 1.67 B | 1.67 B | 1.67 B | 1.61 B | 1.61 B | 1.61 B | 1.61 B | 1.79 B | 1.79 B | 1.79 B | 1.79 B | 1.84 B | 1.86 B | 1.86 B | 1.86 B | 2.05 B | 2.09 B | 2.09 B | 2.09 B | 1.98 B | 1.98 B | 1.98 B | 1.98 B | 836 M | 836 M | 836 M | 836 M | 873 M | 873 M | 873 M | 873 M | 203 M | 203 M | 203 M | 203 M | 185 M | 185 M | 185 M | 185 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.09 B | 185 M | 1.37 B |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
5.39 B | $ 118.25 | -1.27 % | $ 35.9 B |  USA |
 |
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 22.5 | 9.44 % | $ 242 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M |  Israel |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
CareDx, Inc
CDNA
|
303 M | $ 22.42 | 27.6 % | $ 1.19 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M |  Britain |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Co-Diagnostics
CODX
|
20.6 M | $ 1.46 | 2.82 % | $ 1.94 M | USA |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | USA |
 |
Castle Biosciences
CSTL
|
456 M | $ 24.56 | -0.24 % | $ 682 M | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
Charles River Laboratories International
CRL
|
3.21 B | $ 176.94 | -2.0 % | $ 8.77 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | USA |
 |
Danaher Corporation
DHR
|
83.5 B | $ 193.78 | -2.18 % | $ 138 B | USA |
 |
Interpace Biosciences
IDXG
|
22.4 M | $ 2.2 | - | $ 9.73 M | USA |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
6.3 B | $ 132.72 | 0.35 % | $ 21.1 B | USA |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 16.13 | -0.25 % | $ 488 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
11 B | $ 28.63 | -1.58 % | $ 20 B |  Niderland |
 |
Medpace Holdings
MEDP
|
459 M | $ 515.65 | -0.56 % | $ 14.9 B | USA |
 |
Guardant Health
GH
|
-99.3 M | $ 85.7 | 0.99 % | $ 10.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | Niderland |
 |
Anixa Biosciences
ANIX
|
14 M | $ 2.83 | -3.41 % | $ 91.8 K | USA |
 |
Biomerica
BMRA
|
4.1 M | $ 2.2 | 4.27 % | $ 5.05 M | USA |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
9.52 B | $ 115.58 | -0.79 % | $ 9.53 B |  Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 266.36 | -0.14 % | $ 22.2 B | USA |
 |
Celcuity
CELC
|
101 M | $ 125.25 | 1.44 % | $ 5.86 B | USA |
 |
Lantheus Holdings
LNTH
|
1.09 B | $ 83.92 | -0.02 % | $ 5.66 B | USA |
 |
Myriad Genetics
MYGN
|
368 M | $ 5.0 | -3.66 % | $ 463 M | USA |
 |
NeoGenomics
NEO
|
837 M | $ 8.16 | -5.99 % | $ 1.05 B | USA |
 |
Neogen Corporation
NEOG
|
2.07 B | $ 9.24 | -1.91 % | $ 2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 191.46 | 0.02 % | $ 21.3 B | USA |
 |
ENDRA Life Sciences
NDRA
|
2.26 M | $ 5.17 | 0.58 % | $ 4.07 M | USA |
 |
National Research Corporation
NRC
|
14 M | $ 17.62 | -1.23 % | $ 394 M | USA |
 |
Invitae Corporation
NVTA
|
102 M | - | - | $ 21.2 M | USA |
 |
Natera
NTRA
|
706 M | $ 196.11 | -5.35 % | $ 19.3 B | USA |
 |
Organovo Holdings
ONVO
|
10.5 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
7.38 M | - | -16.95 % | $ 1.54 M | USA |
 |
PerkinElmer
PKI
|
7.25 B | - | -0.91 % | $ 14.7 B | USA |